ArticleBMC veterinary research2026
Longitudinal echocardiographic systolic changes in dogs receiving doxorubicin-based chemotherapy.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin is widely used in veterinary oncology but carries a risk of cumulative cardiotoxicity. Serial echocardiographic evaluation is commonly used to monitor dogs receiving potentially cardiotoxic chemotherapy; however, evidence remains limited regarding which indices best capture early longitudinal systolic changes. Conventional monitoring relies largely on fractional shortening and M-mode estimated ejection fraction, which are based on geometric assumptions and may have limited sensitivity for subtle systolic change. This study evaluated whether Simpson-derived left ventricular ejection fraction better captures longitudinal echocardiographic systolic changes than conventional indices in dogs receiving doxorubicin-based chemotherapy. Twenty-nine client-owned dogs were prospectively enrolled, including 23 females and 6 males, with a median age of 10.0 years (IQR, 7.0-11.0) and median body weight of 13.2 kg (IQR, 7.0-21.6). Twelve dogs received doxorubicin as monotherapy and 17 received combination protocols. Echocardiography was performed before the first cycle (D0) and after three consecutive cycles (D1, D2, D3).
resultsSimpson-derived left ventricular ejection fraction (LVEF) showed a progressive numerical decline from 72.0 ± 7.3% at baseline to 66.5 ± 7.7% at D3; however, no individual time-point estimate reached statistical significance in the mixed-effects model (D1, p = 0.183; D2, p = 0.618; D3, p = 0.206). M-mode estimated LVEF and fractional shortening did not show comparable directional patterns or significant longitudinal changes. A decline greater than 10% points in Simpson-derived LVEF was identified in 9 of 29 dogs (31.0%), all while absolute values remained within conventional reference limits. Six of these dogs were not identified by either conventional index.
conclusionsSerial, baseline-referenced Simpson-derived LVEF identified more longitudinal echocardiographic systolic changes than conventional indices in this cohort. These findings suggest that Simpson-derived LVEF may provide complementary information for tracking baseline-referenced systolic changes in dogs receiving doxorubicin. However, these changes should not be interpreted as definitive evidence of myocardial injury, and their clinical relevance requires confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.